Eagle Pharmaceuticals Inc (EGRX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Scott L. Tarriff
Employees:
100
50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE, NJ 07677
201-326-5300

Eagle Pharmaceuticals, Inc. focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology. The company offers Ryanodex for malignant hyperthermia; Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure.

Data derived from most recent annual or quarterly report
Market Cap 109.61 Million Shares Outstanding12.987 Million Avg 30-day Volume 125.97 Thousand
P/E Ratio21.4032 Dividend Yield0.0 EPS-0.74
Price to Revenue0.9929 Debt to Equity0.2785 EBITDA56.798 Million
Price to Book Value1.0146 Operating Margin15.9211 Enterprise Value310.564 Million
Current Ratio2.162 EPS Growth-0.497 Quick Ratio1.506
1 Yr BETA 0.9717 52-week High/Low 36.55 / 8.32 Profit Margin4.6391
Operating Cash Flow Growth-126.2265 Free Cash Flow to Firm (FCFF) TTM -38.802 Million Free Cash Flow to Equity (FCFE) TTM213.818 Million
Altman Z-Score2.6473
View SEC Filings from EGRX instead.

View recent insider trading info

Eagle Pharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding EGRX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding EGRX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-11-03 by TARRIFF SCOTT
  • 4: filed on 2023-10-31 by GRAVES MICHAEL
  • 4: filed on 2023-10-04 by TARRIFF SCOTT
  • 4: filed on 2023-05-18 by TARRIFF SCOTT
  • 4: filed on 2023-05-15 by TARRIFF SCOTT
  • 4: filed on 2023-03-02 by CAHILL BRIAN JOSEPH
  • 4: filed on 2023-03-02 by TARRIFF SCOTT
  • 4: filed on 2023-02-06 by CAHILL BRIAN JOSEPH
  • 4: filed on 2023-01-31 by CAHILL BRIAN JOSEPH
  • 4: filed on 2023-01-24 by TARRIFF SCOTT

    • Events (8k)

  • 8-K: filed on 2023-11-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-10-24:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-10-23:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-09-27:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-09-07:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-29:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-17:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-07-31:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-07-24:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

  • 144: filed on 2023-05-11:
  • 144: filed on 2023-10-02:
  • 144: filed on 2023-10-03:
  • 144: filed on 2023-11-01:
  • 144: filed on 2023-11-02:

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    41.9 Thousand total shares from 5 transactions

    Exercise Derivative Conversion (M)

    9.4 Thousand total shares from 1 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    TARRIFF SCOTT CEO

    • Officer
    • Director
    • 10% Owner
    		 2,094,211 2023-11-01 7

    GRAVES MICHAEL

    • Director
    		 10,360 2023-10-27 2

    RATOFF STEVEN B

    • Director
    		 0 2023-03-07 1

    SIMPSON JENNIFER K.

    • Director
    		 0 2023-03-07 1

    GLENNING ROBERT

    • Director
    		 0 2023-03-07 1

    EDLIN RICHARD A.

    • Director
    		 0 2023-03-07 1

    BORIO LUCIANA

    • Director
    		 0 2023-03-07 1

    CAHILL BRIAN JOSEPH CHIEF FINANCIAL OFFICER

    • Officer
    		 47,868 2023-02-28 5

    MORAN MICHAEL SHAWN EVP, CHIEF COMMERCIAL OFFICER

    • Officer
    		 32,115 2022-02-28 0

    PERNOCK DAVID PRES & CHIEF OPERATING OFFICER

    • Officer
    		 54,625 2021-02-02 0

    NG-CASHIN JUDITH CHIEF MEDICAL OFFICER

    • Officer
    		 2,000 2021-02-02 0

    MEYERS PETE A. CHIEF FINANCIAL OFFICER

    • Officer
    		 43,615 2020-01-23 0

    HEPNER ADRIAN EVP AND CHIEF MEDICAL OFFICER

    • Officer
    		 48,784 2020-01-23 0

    HUDSON EXECUTIVE CAPITAL LP

    HEC MANAGEMENT GP LLC

    BRAUNSTEIN DOUGLAS L

    • Director
    		 732,777 2019-10-24 0

    BRAUNSTEIN DOUGLAS L

    • Director
    		 811,777 2019-05-09 0

    FLAUM SANDER A

    • Director
    		 13,510 2019-03-05 0

    KRILL STEVEN L. EVP & CHIEF SCIENTIFIC OFFICER

    • Officer
    		 3,000 2018-01-07 0

    PROQUEST INVESTMENTS IV, L.P.

    PROQUEST FINANCIAL LLC

    PROQUEST ASSOCIATES IV LLC

    MOORIN JAY

    SCHREIBER ALAIN

    • 10% Owner
    		 No longer subject to file 2017-05-15 0

    RIGGS DAVID E CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2017-01-04 0

    PROQUEST MANAGEMENT LLC

    PROQUEST INVESTMENTS IV, L.P.

    PROQUEST ASSOCIATES IV LLC

    MOORIN JAY

    SCHREIBER ALAIN

    • Director
    • 10% Owner
    		 4,780,188 2016-05-20 0

    PROQUEST FINANCIAL LLC

    • 10% Owner
    		 4,780,188 2016-05-20 0

    MOORIN JAY

    • Director
    • 10% Owner
    		 0 2016-01-04 0

    SCHREIBER ALAIN

    • Director
    		 0 2016-01-04 0

    BRUINENBERG PAUL CHIEF MEDICAL OFFICER

    • Officer
    		 0 2014-08-26 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    TARRIFF SCOTT - Director - Officer - > 10% Owner CEO

    		2023-11-03 16:39:26 -0400 2023-11-02 S 10,694 $13.87 d 545,447 direct yes -0.1427 -32.2397 0.0 1 -33.8802 5

    TARRIFF SCOTT - Director - Officer - > 10% Owner CEO

    		2023-11-03 16:39:26 -0400 2023-11-01 S 10,925 $13.82 d 556,141 direct yes -0.1427 -32.2397 0.0 1 -33.8802 5

    GRAVES MICHAEL - Director

    		2023-10-31 17:41:24 -0400 2023-10-27 M 9,360 $4.94 a 10,360 direct 1.364 -1.6511 3.5176 3 -1.6511 6

    GRAVES MICHAEL - Director

    		2023-10-31 17:41:24 -0400 2023-10-27 M 9,360 d 0 direct

    TARRIFF SCOTT - Director - Officer - > 10% Owner CEO

    		2023-10-04 17:07:25 -0400 2023-10-03 S 710 $15.11 d 567,066 direct yes -2.9412 -8.8235 -39.4958 0.9804 22 -39.4958 31

    TARRIFF SCOTT - Director - Officer - > 10% Owner CEO

    		2023-10-04 17:07:25 -0400 2023-10-03 S 10,024 $14.41 d 567,776 direct yes -2.9412 -8.8235 -39.4958 0.9804 22 -39.4958 31

    TARRIFF SCOTT - Director - Officer - > 10% Owner CEO

    		2023-10-04 17:07:25 -0400 2023-10-02 S 9,511 $15.23 d 577,800 direct yes -2.9412 -8.8235 -39.4958 0.9804 22 -39.4958 31

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    EAGLE PHARMACEUTICALS INC EGRX 2023-11-28 22:15:04 UTC 4.2881 1.0319 950000
    EAGLE PHARMACEUTICALS INC EGRX 2023-11-28 21:45:03 UTC 4.2881 1.0319 950000
    EAGLE PHARMACEUTICALS INC EGRX 2023-11-28 21:15:04 UTC 4.2881 1.0319 950000
    EAGLE PHARMACEUTICALS INC EGRX 2023-11-28 20:45:04 UTC 4.2881 1.0319 950000
    EAGLE PHARMACEUTICALS INC EGRX 2023-11-28 20:15:04 UTC 4.2881 1.0319 950000
    EAGLE PHARMACEUTICALS INC EGRX 2023-11-28 19:45:03 UTC 4.2881 1.0319 950000
    EAGLE PHARMACEUTICALS INC EGRX 2023-11-28 19:15:04 UTC 4.2881 1.0319 950000
    EAGLE PHARMACEUTICALS INC EGRX 2023-11-28 18:45:03 UTC 4.2881 1.0319 950000
    EAGLE PHARMACEUTICALS INC EGRX 2023-11-28 18:15:03 UTC 4.2881 1.0319 950000
    EAGLE PHARMACEUTICALS INC EGRX 2023-11-28 17:45:04 UTC 4.2791 1.0409 950000
    EAGLE PHARMACEUTICALS INC EGRX 2023-11-28 17:15:04 UTC 4.2791 1.0409 950000
    EAGLE PHARMACEUTICALS INC EGRX 2023-11-28 16:45:04 UTC 4.2791 1.0409 950000
    EAGLE PHARMACEUTICALS INC EGRX 2023-11-28 16:15:04 UTC 4.2791 1.0409 950000
    EAGLE PHARMACEUTICALS INC EGRX 2023-11-28 15:45:03 UTC 4.8789 0.4411 950000
    EAGLE PHARMACEUTICALS INC EGRX 2023-11-28 15:15:03 UTC 4.8789 0.4411 950000
    EAGLE PHARMACEUTICALS INC EGRX 2023-11-28 14:45:04 UTC 4.8695 0.4505 950000
    EAGLE PHARMACEUTICALS INC EGRX 2023-11-28 14:15:04 UTC 4.8695 0.4505 950000
    EAGLE PHARMACEUTICALS INC EGRX 2023-11-28 13:45:04 UTC 2.5814 2.7386 950000
    EAGLE PHARMACEUTICALS INC EGRX 2023-11-28 13:15:03 UTC 2.5814 2.7386 950000
    EAGLE PHARMACEUTICALS INC EGRX 2023-11-28 12:45:04 UTC 2.5814 2.7386 950000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Enhanced Index Plus Fund EGRX -47.0 shares, $-2162.0 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund EGRX -22.0 shares, $-1012.0 2020-03-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments